The use of thyrogen® in the treatment of differentiated thyroid carcinoma: An intraindividual comparison of clinical effects and implications of daily life

Experimental and Clinical Endocrinology and Diabetes

Volumn 118, Issue 8, 2010, Pages 513-519

  Dueren, C ^a   Dietlein, M ^b   Luster, M ^c   Plenzig, F ^d   Steinke, R ^e   Grimm, J ^f   Groth, P ^g   Eichhorn, W ^h   Reiners, C ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d Genzyme GmbH   (Germany)

^e Center of Nuclear Medicine   (Germany)

^f Center of Nuclear Medicine   (Germany)

^g UNIVERSITY OF ROSTOCK   (Germany)

^h JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

diagnostic whole body.; hypothyroidism; rhTSH; thyroid cancer

Indexed keywords

IODINE 131; LEVOTHYROXINE; LIOTHYRONINE; RECOMBINANT THYROTROPIN; THYROXINE; THYROGLOBULIN;

ABSENTEEISM; ADULT; ANGINA PECTORIS; ARTICLE; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DIARRHEA; DIFFERENTIATED THYROID CARCINOMA; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERANCE; DRUNKENNESS; ECONOMIC ASPECT; EMPLOYMENT; EPISODIC VERTIGO; EUTHYROIDISM; FATIGUE; FEMALE; FLU LIKE SYNDROME; GERMANY; HEART PALPITATION; HOT FLUSH; HUMAN; HYPERHIDROSIS; HYPOTHYROIDISM; INTERMETHOD COMPARISON; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 12; SYMPTOM; THYROID CARCINOMA; TREATMENT WITHDRAWAL; VERTIGO; WHOLE BODY SCINTISCANNING; ADENOCARCINOMA; BLOOD; CANCER STAGING; MIDDLE AGED; PAPILLARY CARCINOMA; PATHOLOGY; PROSPECTIVE STUDY; THYROID TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA, FOLLICULAR; ADULT; CARCINOMA, PAPILLARY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; QUALITY OF LIFE; THYROGLOBULIN; THYROID NEOPLASMS; THYROTROPIN ALFA; TREATMENT OUTCOME;

EID: 77956961870     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0029-1234086     Document Type: Article

References (29)

1. Billewicz WZ, Chapman RS, Crooks J et al. Statistical methods applied to the diagnosis of hypothyroidism. Q J Med 1969 38 (150) 255-266
2. Borget I, Corone C, Nocaudie M et al. Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with thyrogen and thyroid hormone withdrawal. Eur J Endocrin 2007 156 (5) 531-538
3. Borget I, Remy H, Chevalier J et al. Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen. Eur J Nucl Med Mol Imaging 2008 35 (8) 1457-1463
4. Botella-Carretero JI, Gomez-Bueno M, Barrios V et al. Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma. Endocrine-Related Cancer 2004 11 (2) 345-356
5. Cohen O, Dabhi S, Karasik A et al. Compliance with follow-up and the informative value of diagnostic whole-body scan in patients with differentiated thyroid carcinoma given recombinant human TSH. Eur J Endocrin 2004 150 (3) 285-290
6. Constant EL, de Volder AG, Ivanoiu A et al. Cerebral blood flow and glucose metabolism in hypothyroidism: a positron emission tomography study. J Clin Endocrinol Metabol 2001 86 (8) 3864-3870
7. Dietlein M, Dressler J, Eschner W et al. Procedure guideline for I-131 whole-body scintigraphy for differentiated thyroid cancer (version 2). Nuklearmedizin 2003 42 (3) 123-125
8. Dietlein M, Dressler J, Eschner W et al. Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 3). Nuklearmedizin 2007 46 (5) 206-212
9. Dietlein M, Dressler J, Escher W et al. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3). [German]. Nuklearmedizin 2007 46 (5) 213-219 (Pubitemid 47612288)
10. Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997 7 (4) 613-619
11. Duntas LH, Biondi B. Short-term hypothyroidism after levothyroxine- withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences. Eur J Endocrinol 2007 156 (1) 13-19
12. Franchini M. Hemostatic changes in thyroid diseases. Hematology 2006 11 (3) 203-208
13. Gandek B, Sinclair SJ, Kosinski M et al. Psychometric evaluation of the SF-36 health survey in Medicare managed care. Health Care Financ Rev 1998 25 (4) 5-25
14. Goldberg P. Life-threatening hypothyroidism during thyroid hormone withdrawal for routine thyroid cancer surveillance. Endocrinologist 2007 17 (2) 116-118
15. Haugen BR, Cooper DS, Emerson CH et al. Expanding indications for recombinant human TSH in thyroid cancer. Thyroid 2008 18 (7) 687-694
16. den Hollander JG, Wulkan RW, Mantel MJ et al. Correlation between severity of thyroid dysfunction and renal function. Clin Endocrinol 2005 62 (4) 423-427
17. Leboeuf R, Perron P, Carpentier AC et al. L-T3 preparation for whole-body scintigraphy: a randomized-controlled trial. Clin Endocrinol (Oxf) 2007 67 (6) 839-844
18. Lien EA, Nedrebo BG, Varhaug JE et al. Plasma total homocysteine levels during short-term iatrogenic hypothyroidism. J Clin Endocrinol Metabol 2000 85 (3) 1049-1053
19. Luster M. Present status of the use of recombinant human TSH in thyroid cancer management. Acta Oncol 2006 45 (8) 1018-1030
20. Luster M, Felbinger R, Dietlein M et al. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 2005 15 (10) 1147-1155
21. Mernagh P, Campbell S, Dietlein M et al. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. Eur J Endocrinol 2006 155 (3) 405-414
22. M̈nte TF, Lill C, Otting G et al. Cognitive changes in short-term hypothyroidism assessed with event-related brain potentials. Psychoneuroendocrinology 2004 29 (9) 1109-1118
23. Nagamachi S, Jinnouchi S, Nishii R et al. Cerebral blood flow abnormalities induced by transient hypothyroidism after thyroidectomy Analysis by Tc-99m-HMPAO and SPM96. Ann Nucl Med 2004 18 (6) 469-477
24. Nijhuis TF, van Weperen W, de Klerk JMH. Costs associated with the withdrawal of thyroid hormone suppression therapy during the follow-up treatment of well-differentiated thyroid cancer. Tijdschr Nucl Geneeskd 1999 21 98-100
25. Reiners C, Dietlein M, Luster M. Radio-iodine therapy in differentiated thyroid cancer: indications and procedure. Best Pract Res Clin Endocrinol Metab. 2008 22 (6) 989-1007. Review
26. Rosenthal MS. The impaired hypothyroid patient: ethical considerations and obligations. Thyroid 2007 17 (12) 1261-1267
27. Schroeder PR, Haugen BR, Pacini F et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 2006 91 (3) 878-884
28. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996 34 (3) 220-233
29. Woolam GL. Cancer statistics, 2000: a benchmark for the new century. CA Cancer J Clin 2000 50 (1) 6